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Methods for the estimation of pyrazinamide in serum and of pyrazinamide and pyra-
zinoic acid in urine using an anion-exchange resin (Dowex-1) have been described.
Recoveries were quantitative, and the sensitivity was 5 µg/ml for ail 3 estimations.
In serum, pyrazinoic acid at a concentration of 50 µg/ml did not interfere with the
estimation of pyrazinamide. In urine, pyrazinamide and pyrazinoic acid could
be separated from each other and estimated even when the 2 compounds were
present together at concentrations of 2000 µg/ml each.
Studies on the pharmacology of
pyrazinamide have gained importance
in view of the suitability of this drug for
short-course chemotherapy of tubercu-
losis1. Pyrazinamide is usually estimated
in body fluids by reaction with alkaline
nitroprusside. However, pyrazinoic acid–
the principal metabolite of pyrazinamide,
also reacts with nitroprusside under these
conditions.For separation of pyrazina-
mide from pyrazinoic acid in body fluids,
Ellard2 used a solvent extraction proce-
dure while Subbammal and associates3
used an anion-exchange resin. In the
latter method, described from our Centre
for the estimation of pyrazinamide in
serum, the entire eluate is used, and if a
repetition becomes necessary, the entire
procedure starting from serum has to be
repeated. To overcome this difficulty,
we have modified the procedure slightly
and have also extended it to the estima-
ti n of pyrazinamide and pyrazinoic acid
in urine.
Material and Methods
Estimation of pyrazinamide in serum : To
3.5 ml of serum was added 1.8 ml of 10
per cent trichloroacetic acid and the
contents were stirred and centrifuged.
T re  ml of the protein-free supernate
was applied to a column (75 x 6 mm) of
Dowex 1- x 8 (Cl-form, 200-400 mesh)
and the column was washed with small
mounts of water till 10 ml of the eluate
was collected.Three ml of this eluate was
treat d with 0.5 ml of a freshly prepared
solution of 0.2 per cent sodium nitro-
prusside in water followed by 0.5 ml of
2N sodium hydroxide solution. The tubes
were left at room temperature for 15 min
and the optical densities were recorded
at 495 nm in one cm cells in a Unicam
SP 600 spectrophotometer.
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Estimation of pyrazinamide and pyrazinoic
acid in urine : Three ml of urine were app-
lied to the column of the anion-exchange
resin and pyrazinamide was eluted from
the column by washing it with small
amounts of water till 15 ml of the eluate
was collected. For pyrazinoic acid, the
column was first washed with 15 ml of
water followed by small amounts of 0.5M
sodium chloride solution till 15 ml of the
eluate was collected. Three ml of the
respective eluates were treated with
alkaline nitroprusside and the optical
densities recorded as described for serum.
Results
Recovery of pyrazinamide from serum :
On each of 5 occasions, pyrazinamide
was set up, in duplicate, in concentra-
tions of 0, 2.5, 5, 10, 25, 50 and 100 µg/ml
in horse serum. The serum samples
were randomised and the optical densi-
ties were recorded as described before.
Another set of pyrazinamide concentra-
tions (as above), in duplicate, in horse
serum was processed directly, i.e., 3 ml of
the protein-free supernate (after a 3 in
10 dilution) was directly reacted with
alkaline nitroprusside solution and the
optical densities recorded. Water
standards in the concentrations mention-
ed were also set up concurrently on each
occasion and processed directly. The
geometric mean optical densities are
presented in Table I.
Results showed that with the ion-
exchange method, the optical density was
proportional to the concentration of
pyrazinamide over the range tested.
Comparison with serum and water stan-
dards processed directly showed that re-
covery of pyrazinamide from serum was
quantitative. The coefficient of varia-
tion for replicate estimations with the
ion-exchange method was 19.5 per cent
for a concentration of 2.5 µg/ml and
3-5 per cent for concentrations of
5-100 µg/ml.
Readings obtained with water blanks
were much higher than those obtained
with horse serum, the mean optical
densities being 0.137 and 0.044, respec-
tively.
Blank sera from different patients : Blood
was collected from 15 patients not recei-
ving pyrazinamide, serum separated and
the serum samples processed for estima-
tion of pyrazinamide. The blank read-
ings for the different specimens ranged
from 0.090 to 0.098, but the differences
wer  not significant statistically (P>0.2).
The mean optical density for the 15
patients was 0.094, which was consider-
ably lower than the mean optical density
with water standards (0.137) and consi-
derably higher than that with horse
se um (0.044). This suggests that it is
essential to employ human serum blanks
for estimating serum pyrazinamide con-
centrations in human subjects. As the
blank readings from different patients
wer  similar, pooled human serum can
be employed for setting up blanks.
Recovery of pyrazinamide and pyrazinoic
acid from urine : On each of 5 occasions,
pyrazinamide and pyrazinoic acid were
set up, in duplicate, in concentrations of
0, 5, 10, 25, 50 and 100 µg/ml in pooled
normal urine (from volunteers). Optical
densities were determined by the ion-
exchange method described above as well
as by the direct processing method.
The geometric mean optical densities
re presented in Table II. The results
indicate that with both pyrazinamide and
pyrazinoic acid, Beer’s law is followed
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Table I. Optical density readings with pyrazinamide in horse serum and water
Method
Mean optical density* with the following concentrations
of pyrazinamide (µg/ml)






Horseserum Ion-exchange 0.020 0.036 0.064 0.139 0.284 0.558 0.046
Direct 0.020 0.038 0.068 0.142 0.288 0.555 0.044
Water Direct 0.015 0.033 0.062 0.141 0.286 0.562 0.137
*After subtracting values obtained with blanks.
Table II. Optical density readings with pyrazinamide and pyrazinoic acid in urine
Method
Mean optical density* with the following concentrationsMea
of pyrazinamide and pyrazinoic acid (µg/ml)optical
density
with
5 10 25 50 100 blanks
Pyrazinamide Ion-exchange0.024 0.047 0.111 0.222 0.441 0.015
Direct 0.023 0.045 0.108 0.223 0.439 0.033
Pyrazinoicacid Ion-exchange 0.022 0.044 0.107 0.210 0.413 0.019
Direct 0.022 0.044 0.105 0.211 0.413 0.031
*After subtracting values obtained with blanks.
over the range 5-100 µg/ml. Comparison
with urine standards processed directly
indicates a quantitative recovery of both
the compounds from urine. With the
ion-exchange method, the coefficient of
variation for replicate estimations at a
concentration of 5 µg/ml was 5.7 per cent
for pyrazinamide and 4.8 per cent for
pyrazinoic acid,and 3-6 per cent for
both in concentrations of 10-100 µg/ml.
Sensitivity of the methods : Sensitivity
of the method has been regarded as the
lowest concentration where the co-
efficient of variation for replicate esti-
ma ions is 10 per cent or less. In the
estimation of pyrazinamide in serum, the
coefficient of variation was 19.5 per cent
a a concentration of 2.5 µg/ml and
4.8 per cent at 5 µg/ml; in urine, the
co fficients of variation at 5 µg/ml were
5.7 per cent for pyrazinamide and 4.8 per
cent for pyrazinoic acid.The sensitivity
of all the three methods is, therefore,
5 µg/ml.
The sensitivity of the method for
estimation of pyrazinamide in serum
(5 µg/ml) was not a serious limitation as
this concentration is well below the
minimum inhibitory concentration of
pyrazinamide, reported to be between
9 and 16 µg/ml. in a Tween-free high
citrate medium (pH 5.6)4,5.
Interference studies
Pyrazinamide in serum : On each
of 3 occasions, pyrazinoic acid in con-
centrations of 0 and 50 µg/ml was added
to pyrazinamide concentrations of 0, 10,
25 and 50 µg/ml set up in horse serum,
and the optical densities determined after
randomisation of the specimens.The
blank readings for pyrazinamide were
the same both in the absence and in the
presence of pyrazinoic acid (viz.,0.087).
The mean optical densities were 0.060,
0.142 and 0.274 with pyrazinamide con-
centrations of 10, 25 and 50 µg/ml in the
absence of pyrazinoic acid, and 0.070,
0.149 and 0.274 respectively, in the pre-
sence of pyrazinoic acid 50 µg/ml,
demonstrating that pyrazinoic acid did
not interfere with the estimation of pyra-
zinamide. However, if a 30 per cent
solution of trichloroacetic acid is used,
instead of 10 per cent solution emplo-
yed here, exchange of pyrazinoic acidis
diminished considerably (unpublished
observation) as the stronger trichloroace-
tic acid is exchanged in preference to
pyrazinoic acid and the latter is eluted
out with water itself.
Pyrazinamide and pyrazinoic acid in
urine : On each of 4 occasions, pyrazi-
noic acid 0 and 2000 µg/ml was added
to pyrazinamide concentrations of 0 and
2000 µg/ml in pooled normal urine and
the optical densities determined for both
the compounds after a 3 in 50 dilution
of the respective eluates. Concurrently,
dards of 2000 µg/ml in urine were pro-
cessed directly after a 3 in 50 dilution
of the samples. The mean optical den-
siti s for pyrazinamide 2000 µg/ml alone
and in the presence of pyrazinoic acid
2000 µg/ml were 0.592 and 0.590, respec-
tively. On direct reaction, pyrazinamide
2000 µg/ml gave a reading of 0.593. The
mean optical densities for pyrazinoic acid
2000 µg/ml alone and in the presence of
pyrazinamide 2000 µg/ml were 0.562 and
0.561, respectively.On direct reaction,
pyrazinoic acid 2000 µg/ml gave a read-
ing of 0.555.These findings demonstrate
that in urine, effective separation of
pyrazinamide from pyrazinoic acid was
achieved even when these two com-
pounds were present together at concen-
trations of 2000 µg/ml each, and also
that the elution of both was quantitative
even at these high concentrations.
Interference due to some anti-
tuberculosis drugs : Streptomycin, p-
aminosalicylic acid, thioacetazone, rifam-
picin, ethambutol,ethionamide and
cycloserine in concentrations up to 500
µg/ml did not interfere with the estima-
tion of either pyrazinamide or pyrazinoic
acid (0, 10 and 25 µg/ml) in urine.
Neither did isoniazid, but acetylisonia-
zid caused a significant over-estimation
of pyrazinamide. For example, acetyl-
isoniazid 100µg/ml gave an optical
density reading equivalent to that obtain-
ed with pyrazinamide 7.5 µg/ml; the esti-
mation of pyrazinoic acid was, however,
not affected. It is, therefore, necessary
to withhold isoniazid for at least 48 h
prior to any pharmacological investiga-
tio s with pyrazinamide.
Discussion
The methods described here for the
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pyrazinamide and pyrazinoic acid stan-estimation of pyrazinamide and pyrazi-
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noic acid are fairly simple and quite
specific, as prior separation of the two
is achieved with the use of an anion-
exchange resin. When an aqueous solu-
tion containing a mixture of pyrazinamide
and pyrazinoic acid is passed through an
anion-exchange resin, pyrazinoic acid is
retained on the column and is eluted only
with a neutral salt solution (0.5 M
sodium chloride solution was used in our
studies).
This procedure can also be used to
estimate pyrazinoic acid in serum. Pyra-
zinoic acid can be eluted from the column
with 10 ml of 0.5 M sodium chloride
solution following removal of pyrazina-
mide with water.The method will have
only a limited applicability as the sensi-
tivity is likely to be 5 µg/ml, and Ellard2
has shown that peak serum concentra-
tions of pyrazinoic acid did not exceed
10 µg/ml in African patients receiving
pyrazinamide 3 g.
In the estimation of pyrazinamide
and pyrazinoic acid reported here, water
blanks gave higher readings than horse
serum, human serum or urine blanks.
(The lower readings obtained with horse
and human sera and urine may be due to
an inhibition of the nitroprusside reac-
tion due to increasing concentrations of
ammonia present in these samples2).
Dilution of the samples (or the eluates)
with water would therefore result in
higher optical density readings. When
such a dilution becomes necessary (for
samples containing high concentrations
of pyrazinamide or pyrazinoic acid), it
is essential to dilute the blanks also
similarly.
In the estimation of pyrazinamide
and pyrazinoic acid in urine, it has been
obs rved that a column containing the
anion-exchange resin can be re-used at
least 10 times (unpublished observation)
a  the resin is regenerated at the time of
elution of pyrazinoic acid from the
column with 0.5 M sodium chloride
solution. In the case of the estimation of
pyrazinamide in serum, however, it will be
necessary to regenerate the resin by wash-
ing it with 0.5 M sodium chloride solution
following elution of pyrazinamide with
water. In routine practice, it is advisable
to wash the column with 15 to 20 ml of
water, after treatment with sodium chlo-
ride solution, prior to application of the
fresh sample.
The solvent extraction procedure
described by Ellard2 for estimation of
pyrazinamide in serum is more sensitive
(1 µg/ml) than that reported here. The
two methods are of the same sensitivity
for estimation of pyrazinamide and
pyrazinoic acid in urine. In the procedure
described by Ellard2, a slight interference
of 3.2 per cent due to pyrazinamide in
the estimation of pyrazinoic acid has
been reported; also, care has to be taken
to avoid prolonged contact of pyrazina-
mide with alkali. The methods described
by us here have fewer steps. Further,
pyrazinamide and pyrazinoic acid do not
interfere with the estimation of each
other in urine; nor does pyrazinoic acid
interfere with the estimation of pyrazina-
mide in serum.
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